ERK activity in mutant BRAF melanoma - A live report

被引：0
|
作者：
Aplin, Andrew E. [1 ]
机构：
[1] Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA
来源：
CLINICAL CANCER RESEARCH | 2015年 / 21卷
关键词：
D O I：
10.1158/1557-3265.PMS14-IA18
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
IA18
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma
    Wong, Deborah J. L.
    Robert, Lidia
    Atefi, Mohammad S.
    Lassen, Amanda
    Avarappatt, Geetha
    Cerniglia, Michael
    Avramis, Earl
    Tsoi, Jennifer
    Foulad, David
    Graeber, Thomas G.
    Comin-Anduix, Begonya
    Samatar, Ahmed
    Lo, Roger S.
    Ribas, Antoni
    MOLECULAR CANCER, 2014, 13
  • [2] Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma
    Deborah JL Wong
    Lidia Robert
    Mohammad S Atefi
    Amanda Lassen
    Geetha Avarappatt
    Michael Cerniglia
    Earl Avramis
    Jennifer Tsoi
    David Foulad
    Thomas G Graeber
    Begonya Comin-Anduix
    Ahmed Samatar
    Roger S Lo
    Antoni Ribas
    Molecular Cancer, 13
  • [3] Antitumor Activity of BRAF Inhibitor and IFNα Combination in BRAF-Mutant Melanoma
    Sabbatino, Francesco
    Wang, Yangyang
    Scognamiglio, Giosue
    Favoino, Elvira
    Feldman, Steven A.
    Villani, Vincenzo
    Flaherty, Keith T.
    Nota, Sjoerd
    Giannarelli, Diana
    Simeone, Ester
    Anniciello, Anna M.
    Palmieri, Giuseppe
    Pepe, Stefano
    Botti, Gerardo
    Ascierto, Paolo A.
    Ferrone, Cristina R.
    Ferrone, Soldano
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2016, 108 (07):
  • [4] Differential dependency of BRAF-mutant melanoma on ERK2 Versus ERK1
    Crowe, M.
    Zavorotinskaya, T.
    Voliva, C.
    Stuart, D.
    Freeman, A.
    EUROPEAN JOURNAL OF CANCER, 2018, 103 : E52 - E52
  • [5] Erratum to: Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma
    Deborah JL Wong
    Lidia Robert
    Mohammad S Atefi
    Amanda Lassen
    Geetha Avarappatt
    Michael Cerniglia
    Earl Avramis
    Jennifer Tsoi
    David Foulad
    Thomas G Graeber
    Begonya Comin-Anduix
    Ahmed Samatar
    Roger S Lo
    Antoni Ribas
    Molecular Cancer, 14
  • [6] Activity of the ERK1/2 inhibitor ulixertinib (BVD-523) in patients with BRAF and NRAS mutant melanoma
    Sullivan, Ryan J.
    Janku, Filip
    Li, Bob T.
    Wong, Deborah
    Sosman, Jeffrey
    Keedy, Vicki
    Buchbinder, Elizabeth
    Tolcher, Anthony
    Varghese, Anna
    Hyman, David M.
    Flaherty, Keith T.
    Ribas, Antoni
    Carvajal, Richard
    Wang-Gillam, Andrea
    Kluger, Harriet
    Patel, Manish
    Langecker, Peter
    Varterasian, Mary
    Welsch, Dean
    Infante, Jeffrey
    CANCER RESEARCH, 2017, 77
  • [7] Anti-tumor activity of a BRAF inhibitor and IFNα combination in BRAF mutant melanoma
    Sabbatino, Francesco
    Wang, Yangyang
    Scognamiglio, Giosue
    Favoino, Elvira
    Feldman, Steven A.
    Villani, Vincenzo
    Flaherty, Keith T.
    Nota, Sjoerd
    Giannarelli, Diana
    Simeone, Ester
    Anniciello, Anna M.
    Palmieri, Giuseppe
    Pepe, Stefano
    Botti, Gerardo
    Ascierto, Paolo A.
    Ferrone, Cristina R.
    Ferrone, Soldano
    CANCER RESEARCH, 2016, 76
  • [8] Differential activity of MEK and ERK inhibitors in BRAF inhibitor resistant melanoma
    Carlino, Matteo S.
    Todd, Jason R.
    Gowrishankar, Kavitha
    Mijatov, Branka
    Pupo, Gulietta M.
    Fung, Carina
    Snoyman, Stephanie
    Hersey, Peter
    Long, Georgina V.
    Kefford, Richard F.
    Rizos, Helen
    MOLECULAR ONCOLOGY, 2014, 8 (03) : 544 - 554
  • [9] Inhibition of BRAF and MEK in BRAF-mutant melanoma
    Smalley, Keiran S. M.
    Sondak, Vernon K.
    LANCET, 2015, 386 (9992): : 410 - 412
  • [10] BRAF and MEK inhibitors in BRAF-mutant melanoma
    Sharma, Sharan Prakash
    LANCET ONCOLOGY, 2012, 13 (11): : E468 - E468
12345